New
insights into the unique biochemical properties of riboflavin
(Rf), also known as vitamin B2, are leading to the development of
its use not only as a vitamin supplement but also as a potential anti-inflammatory,
immunomodulatory, antioxidant, anticancer, and antiviral agent, where
it may play a role as an inhibitor of viral proteinases. At the same
time, the comparison of the pharmacoactivity of Rf with its known
metabolites, namely, flavin mononucleotide (FMN) and flavin adenine
dinucleotide (FAD), is very complicated due to its poor water solubility:
0.1–0.3 g/L versus 67 g/L for FMN and 50 g/L for FAD, which
is the limiting factor for its administration in clinical practice.
In this study, we report the recrystallization procedure of the type
A Rf crystals into the slightly hydrophobic type B/C and a new hydrophilic
crystal form that has been termed the P type. Our method of Rf crystal
modification based on recrystallization from dilute alkaline solution
provides an unprecedented extremely high water solubility of Rf, reaching
23.5 g/L. A comprehensive study of the physicochemical properties
of type P riboflavin showed increased photodynamic therapeutic activity
compared to the known types A and B/C against clinical isolates of Staphylococcus aureus, Pseudomonas
aeruginosa, Escherichia coli, and Salmonella typhimurium. Importantly,
our work not only demonstrates a simple and inexpensive method for
the synthesis of riboflavin with high solubility, which should lead
to increased bioactivity, but also opens up opportunities for improving
both known and new therapeutic applications of vitamin B2.